Swissmedic reviews Pfizer application for a booster for children aged 5 to 11 years
Bern, 31.05.2022 - Pharmaceutical company Pfizer Schweiz AG has submitted an application to Swissmedic for the COVID-19 paediatric vaccine (Comirnaty® 10 micrograms/dose). The application for a new dosage recommendation is for a booster dose for children aged 5 to 11 years at least 6 months after basic immunisation.
Swissmedic is assessing the benefits and risks of the new dosage recommendation based on the data submitted. The Comirnaty vaccine from Pfizer / BioNTech for children aged 5 to 11 years has been authorised in Switzerland since 10 December 2021. Dosage and use vary from the Comirnaty vaccine for individuals aged 12 years and over. The vaccine used in children has a lower concentration (10 micrograms) and the injection volume (0.25 millilitres) is four times lower than the adult vaccine. A booster is a further dose of vaccine administered to fully vaccinated people with a basic level of immunisation in order to boost the immunological memory.
Address for enquiries
Swissmedic
Media Unit
+41 58 462 02 76
media@swissmedic.ch
Publisher
Swiss Agency for Therapeutic Products
http://www.swissmedic.ch/?lang=2
